EVT.BE - Evotec SE
| Previous close | 20.94 |
| Open | 21.26 |
| Bid | 21.26 x 145200 |
| Ask | 21.90 x 140700 |
| Day's range | 21.26 - 21.67 |
| 52-week range | 14.81 - 29.71 |
| Volume | |
| Avg. volume | 127 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Successful Results Using Sernova’s Cell Pouch System™ with Evotec’s iPSC-Derived Islet-like Clusters for Type 1 Diabetes Presented at the 4th IPITA / HSCI / JDRF Summit
Evotec’s scalable GMP manufacturing process has been designed to produce induced pluripotent stem cell (iPSC)-derived islet-like clusters (ILCs) with high insulin-producing beta cell content as well as glucagon and somatostatin (produced by alpha cells and delta cells, respectively), similar to human isletsThe ILCs are cryopreserved during manufacturing, enabling storage of mass volumes and cost efficient on-demand worldwide delivery as requiredResults from a type 1 diabetes (T1D) preclinical mo
- GlobeNewswire
Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024 for anticipated clinical trial authorization to treat patients with Type 1 Diabetes (T1D) and severe hypoglycemiaiPSC islet-like cluster manufacturing scale-up and tech transfer activities are well under way in preparation for first human clinical evaluationT1D preclinical models with iPSC derived islet clusters transplanted in Sernova’s Cell Pouch has now demonstrated co
- Business Wire
TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen
TORONTO, Canada & HAMBURG, Germany, October 17, 2022--Toronto Innovation Acceleration Partners ("TIAP") and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner. The expansion goes along with a combined investment of US$14M to expedite LAB150 programs towards the formation of new companies.
- GlobeNewswire
Sernova Receives Second Tranche Equity Investment from Evotec of $6.8 Million at a Price of $2.50 Per Share
LONDON, Ontario, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/ XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced that it has completed the second and final tranche of its previously announced private placement with Evotec SE (FSE:EVT) (NASDAQ: EVO) of 2,709,800 common shares of the Company (“Common Shares”) at a price of $2.50 per share for total proceeds of $6,774,500. Upon completion of the second tranch
- Business Wire
Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
HAMBURG, Germany & SEATTLE, August 10, 2022--Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Alpine Immune Sciences, Inc. (NASDAQ: ALPN) today announced that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., expanded a multi-year partnership with Alpine for the development of a commercial process for ALPN-303, an engineered TACI domain with significantly improved potency against the B cell cytokines BAFF and APRIL, being developed for t
